Show simple item record

dc.creatorJovanović, Dragana
dc.creatorRoksandić-Milenković, Marina
dc.creatorKotur-Stevuljević, Jelena
dc.creatorCeriman, Vesna
dc.creatorVukanić, Ivana
dc.creatorSamardžić, Natalija
dc.creatorPopević, Spasoje
dc.creatorIlić, Branislav
dc.creatorGajić, Milija
dc.creatorSimon, Marioara
dc.creatorSimon, Ioan
dc.creatorSpasojević-Kalimanovska, Vesna
dc.creatorBelić, Milica
dc.creatorMirkov, Damjan
dc.creatorŠumarac, Zorica
dc.creatorMilenković, Vladislav
dc.date.accessioned2019-09-02T12:11:04Z
dc.date.available2019-09-02T12:11:04Z
dc.date.issued2019
dc.identifier.issn1452-8258
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/3341
dc.description.abstractBackground: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Methods: Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression >= 50% NSCLC - responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Results: Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1 + NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average SAA1 value compared to other subgroups. Conclusions: It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points.en
dc.publisherDruštvo medicinskih biohemičara Srbije, Beograd i Versita
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175046/RS//
dc.rightsopenAccess
dc.sourceJournal of Medical Biochemistry
dc.subjectsPD-L1en
dc.subjectserum amyloid A1en
dc.subjectbiomarkeren
dc.subjectPD-L1 positive NSCLCen
dc.titleSoluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung canceren
dc.typearticle
dc.rights.licenseARR
dcterms.abstractРоксандић-Миленковић, Марина; Илић, Бранислав; Јовановић, Драгана; Котур-Стевуљевић, Јелена; Вуканић, Ивана; Миленковић, Владислав; Цериман, Весна; Симон, Иоан; Спасојевић-Калимановска, Весна; Попевић, Спасоје; Мирков, Дамјан; Гајић, Милија; Самарджић, Наталија; Белић, Милица; Симон, Мариоара; Шумарац, Зорица;
dc.citation.volume38
dc.citation.issue3
dc.citation.spage332
dc.citation.epage341
dc.citation.other38(3): 332-341
dc.citation.rankM23
dc.identifier.wos000468363100011
dc.identifier.doi10.2478/jomb-2018-0036
dc.identifier.pmid31156344
dc.identifier.scopus2-s2.0-85057603105
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs//bitstream/id/1905/3339.pdf
dc.identifier.rcubconv_4382
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record